Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids

NCT03601052 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Keloid

Interventions

DRUG: Remlarsen
DRUG: Placebo

Sponsor

miRagen Therapeutics, Inc.